AI Engines For more Details: Perplexity Kagi Labs You
Asthma: Cromolyn sodium is used as a preventive medication to manage asthma symptoms and reduce the frequency and severity of asthma attacks. It belongs to the class of medications known as mast cell stabilizers, which work by preventing the release of inflammatory mediators such as histamine from mast cells in the airways. By stabilizing mast cells, cromolyn sodium helps reduce airway inflammation, bronchoconstriction (narrowing of the airways), and the occurrence of asthma symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
Allergic Rhinitis: Cromolyn sodium is also indicated for the management of allergic rhinitis, a condition characterized by inflammation of the nasal mucosa due to allergen exposure. It is available as a nasal spray formulation for the treatment of allergic rhinitis symptoms such as sneezing, itching, runny or stuffy nose, and nasal congestion. Cromolyn sodium acts locally in the nasal passages to inhibit the release of inflammatory mediators and reduce nasal congestion and other allergic symptoms.
Exercise-Induced Bronchoconstriction (EIB): Cromolyn sodium may be used prophylactically to prevent exercise-induced bronchoconstriction, a temporary narrowing of the airways that occurs during or after physical exertion in individuals with asthma or exercise-induced asthma. By inhibiting mast cell degranulation and the release of bronchoconstrictive mediators, cromolyn sodium helps maintain airway patency and prevent symptoms such as coughing, wheezing, and shortness of breath during exercise.
Dosage and Administration: Cromolyn sodium is available in various formulations, including inhalation solution for nebulization, metered-dose inhalers (MDIs), and nasal spray. The dosage and frequency of administration depend on the specific indication being treated, the severity of symptoms, and the individual patient's response to therapy. Cromolyn sodium is typically used on a regular basis to achieve optimal preventive effects and may require several weeks of continuous use to attain maximum benefit.
Side Effects: Cromolyn sodium is generally well-tolerated, with minimal systemic absorption and few reported side effects. Common side effects may include mild irritation or burning sensation in the nose or throat (with nasal spray use), cough, sneezing, and nasal dryness. Rarely, allergic reactions or hypersensitivity reactions to cromolyn sodium may occur, manifesting as skin rash, itching, or swelling. Patients should discontinue use and seek medical attention if they experience signs of an allergic reaction.
Contraindications and Precautions: Cromolyn sodium is contraindicated in individuals with known hypersensitivity to cromolyn sodium or any of its components. It should be used with caution in patients with severe asthma or acute bronchospasm, as it may not provide immediate relief of acute symptoms. Cromolyn sodium is not intended for the treatment of acute asthma attacks or status asthmaticus and should not be used as a rescue medication for sudden worsening of asthma symptoms.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Bifidobacterium longum | Reduces |
species | Lactococcus cremoris | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Enterocloster | genus | Decreases |
0 | 1 | Ruminococcus | genus | Decreases |
0 | 1 | Coprococcus | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Segatella | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | Ruminococcus bromii | species | Decreases |
1 | 0 | Coprococcus comes | species | Decreases |
0 | 1 | Blautia parvula | species | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
0 | 1 | Flavonifractor plautii | species | Decreases |
0 | 1 | Hungatella hathewayi | species | Decreases |
0 | 1 | Coprococcus catus | species | Decreases |
0 | 1 | Dorea longicatena | species | Decreases |
0 | 1 | Lactococcus cremoris | species | Decreases |
0 | 1 | Blautia obeum | species | Decreases |
1 | 0 | Segatella copri | species | Decreases |
1 | 0 | Roseburia intestinalis | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
Acne | 0 | 0 | |
ADHD | 0.3 | 0.2 | 0.5 |
Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
Allergic Rhinitis (Hay Fever) | 0 | 0.1 | 0 |
Allergies | 0.5 | 0.8 | -0.6 |
Allergy to milk products | 0.4 | 0.1 | 3 |
Alzheimer's disease | 0.4 | 0.7 | -0.75 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.2 | 0 |
Ankylosing spondylitis | 0.3 | 0.2 | 0.5 |
Anorexia Nervosa | 0.2 | 0.3 | -0.5 |
Antiphospholipid syndrome (APS) | 0.1 | 0.1 | 0 |
Asthma | 0.1 | 0.1 | 0 |
Atherosclerosis | 0.2 | 0.1 | 1 |
Atrial fibrillation | 0.4 | 0.2 | 1 |
Autism | 1.1 | 0.7 | 0.57 |
Autoimmune Disease | 0 | 0.1 | 0 |
Bipolar Disorder | 0.3 | 0.4 | -0.33 |
Brain Trauma | 0 | 0.3 | 0 |
Cancer (General) | 0 | 0 | |
Carcinoma | 0.3 | 0.2 | 0.5 |
Celiac Disease | 0.1 | 0.4 | -3 |
Cerebral Palsy | 0 | 0.3 | 0 |
Chronic Fatigue Syndrome | 1.4 | 1.2 | 0.17 |
Chronic Kidney Disease | 0.1 | 0.3 | -2 |
Chronic Lyme | 0 | 0 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.2 | 0 |
Chronic Urticaria (Hives) | 0.1 | -0.1 | |
Coagulation / Micro clot triggering bacteria | 0.3 | -0.3 | |
Cognitive Function | 0.2 | 0.1 | 1 |
Colorectal Cancer | 0.4 | 0.1 | 3 |
Constipation | 0.2 | 0 | 0 |
Coronary artery disease | 0.2 | 0.2 | 0 |
COVID-19 | 0.6 | 1.4 | -1.33 |
Crohn's Disease | 0.5 | 0.4 | 0.25 |
cystic fibrosis | 0.1 | -0.1 | |
deep vein thrombosis | 0.2 | 0.3 | -0.5 |
Depression | 1.3 | 1 | 0.3 |
Dermatomyositis | 0 | 0 | |
Eczema | 0 | 0 | |
Endometriosis | 0.2 | 0.4 | -1 |
Epilepsy | 0 | 0 | 0 |
erectile dysfunction | 0 | 0 | |
Fibromyalgia | 0.4 | 0.4 | 0 |
Functional constipation / chronic idiopathic constipation | 0.5 | 0.5 | 0 |
gallstone disease (gsd) | 0.2 | 0.1 | 1 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | -0.1 | |
Generalized anxiety disorder | 0.2 | 0.2 | 0 |
Gout | 0.2 | 0.2 | 0 |
Graves' disease | 0.2 | 0.3 | -0.5 |
Gulf War Syndrome | 0.2 | 0 | 0 |
Hashimoto's thyroiditis | 0.3 | 0.1 | 2 |
Heart Failure | 0.4 | 0.4 | 0 |
Hidradenitis Suppurativa | 0.1 | 0.1 | |
High Histamine/low DAO | 0 | 0.2 | 0 |
hyperglycemia | 0 | 0 | |
Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 0.2 | 0.6 | -2 |
Hypothyroidism | 0.2 | -0.2 | |
Hypoxia | 0 | 0 | |
IgA nephropathy (IgAN) | 0.2 | 0.2 | 0 |
Inflammatory Bowel Disease | 0.1 | 1.4 | -13 |
Insomnia | 0.2 | 0.3 | -0.5 |
Intelligence | 0.2 | 0.1 | 1 |
Intracranial aneurysms | 0.2 | 0.3 | -0.5 |
Irritable Bowel Syndrome | 0.3 | 0.4 | -0.33 |
ischemic stroke | 0.3 | 0 | 0 |
Liver Cirrhosis | 0.5 | 0.5 | 0 |
Long COVID | 1.2 | 1.1 | 0.09 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 0.1 | 0.2 | -1 |
Mast Cell Issues / mastitis | 0.4 | -0.4 | |
ME/CFS with IBS | 0.6 | 0.7 | -0.17 |
ME/CFS without IBS | 0.1 | 0.1 | 0 |
Menopause | 0 | 0 | 0 |
Metabolic Syndrome | 0.7 | 0.6 | 0.17 |
Mood Disorders | 1.3 | 0.8 | 0.63 |
Multiple Sclerosis | 0.5 | 0.5 | 0 |
Multiple system atrophy (MSA) | 0.2 | -0.2 | |
myasthenia gravis | 0 | 0 | |
neuropathic pain | 0.1 | -0.1 | |
Neuropathy (all types) | 0 | 0 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 0.6 | -0.5 |
NonCeliac Gluten Sensitivity | 0 | 0 | 0 |
Obesity | 0.8 | 0.5 | 0.6 |
obsessive-compulsive disorder | 0.7 | 0.3 | 1.33 |
Osteoarthritis | 0 | 0.2 | 0 |
Osteoporosis | 0.3 | 0.3 | |
Parkinson's Disease | 1 | 0.7 | 0.43 |
Polycystic ovary syndrome | 1 | 0.8 | 0.25 |
Postural orthostatic tachycardia syndrome | 0.2 | -0.2 | |
Premenstrual dysphoric disorder | 0 | 0 | |
Primary sclerosing cholangitis | 0.6 | -0.6 | |
Psoriasis | 0.2 | 0.3 | -0.5 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.1 | 0.2 | 4.5 |
Rosacea | 0.4 | 0 | 0 |
Schizophrenia | 0.5 | 0.4 | 0.25 |
scoliosis | 0.2 | 0.3 | -0.5 |
Sjögren syndrome | 0.1 | 0 | 0 |
Sleep Apnea | 0.4 | 0.2 | 1 |
Slow gastric motility / Gastroparesis | 0.2 | 0 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0 | 0 |
Stress / posttraumatic stress disorder | 0.1 | 0.2 | -1 |
Systemic Lupus Erythematosus | 0.2 | 0.3 | -0.5 |
Tic Disorder | 0.2 | 0.1 | 1 |
Type 1 Diabetes | 0.5 | 0.3 | 0.67 |
Type 2 Diabetes | 1.1 | 0.5 | 1.2 |
Ulcerative colitis | 0.1 | 0.6 | -5 |
Unhealthy Ageing | 0.9 | 0.2 | 3.5 |
Vitiligo | 0.2 | 0.3 | -0.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]